Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2

S. Ghezzi, F. Pacciarini, S. Nozza, S. Racca, S. A. Mariani, E. Vicenzi, A. Lazzarin, F. Veglia, G. Tambussi, G. Poli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective

To investigate the impact of intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART) on HIV-1 entry co-receptor use.

Methods

Primary HIV-1 isolates were obtained from 54 HIV-1-positive individuals at baseline and after 12 months using co-cultivation of peripheral blood mononuclear cells (PBMC) with activated PBMC of HIV-negative healthy donors. HIV-1 co-receptor use was determined on U87-CD4 cells.

Results

Fourteen out of the 21 (67%) IL-2-treated individuals harbouring a primary CCR5-dependent (R5) HIV-1 isolate at baseline confirmed an R5 virus isolation after 12 months in contrast to 3 out of 7 (43%) of those receiving cART only. After 12 months, only 1 R5X4 HIV-1 isolate was obtained from 21 cART+IL-2-treated individuals infected with an R5 virus at entry (5%) vs. 2/7 (29%) patients receiving cART alone, as confirmed by a 5-year follow-up on some individuals.

Conclusions

Intermittent IL-2 administration plus cART may prevent evolution towards CXCR4 usage in individuals infected with R5 HIV-1.

Original languageEnglish
Pages (from-to)349-352
Number of pages4
JournalHIV Medicine
Volume11
Issue number5
DOIs
Publication statusPublished - May 2010

Keywords

  • cART
  • CCR5
  • CXCR4
  • HIV isolation
  • IL-2 therapy
  • viremia
  • CHEMOKINE RECEPTOR EXPRESSION
  • SYNCYTIUM-INDUCING PHENOTYPE
  • HIV-INFECTED PATIENTS
  • T-LYMPHOCYTES
  • DISEASE PROGRESSION
  • PROGNOSTIC VALUE
  • THERAPY
  • CORECEPTOR
  • IL-2
  • AIDS

Cite this